Drug repurposing, also known as drug repositioning, is a drug development strategy predicated on the reuse of existing licensed drugs for new medical indications.
+ Drugs taken from libraries containing products known to react with pathways critical e.g. for neurological disorders.
+ Less CMC work to be done (formulation study only).
+ About 3 year faster market entry, since approval could refer to existing publications and approval data from originator.
+ No or limited preclinical Tox/Safety to be conducted.
+ No or limited clinical phase I needs to be done in US.
+ Cost savings.
+ Significantly lower development risk (safety in humans already shown).